Raymond James 47th Annual Institutional Investors Conference
Mar 3, 2026 • 3:25 pm EST
Mar 3, 2026 • 3:25 pm EST
Fiscal Year Ended Dec 31, 2025
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Axogen, Inc.
13631 Progress Blvd
Suite 400
Alachua, FL 32615
Axogen, Inc.
13631 Progress Blvd.
Suite 400
Alachua, FL 32615
investorrelations@axogeninc.com
Broadridge Corporate Issuer Solutions, Inc.
1717 Arch St.
Suite 1300
Philadelphia, PA 19103
T: 215-553-5400